Northwest blames short sellers for stock slump; Novartis partners up for antidepressant R&D;

@FierceBiotech: ICYMI Friday: Biotech notches another $2B VC quarter, but can it last? Story | Follow @FierceBiotech

@JohnCFierce: Shire hit with another setback as FDA rejects top pipeline drug- Does anyone think that Ornskov is a good CEO? Article | Follow @JohnCFierce

@DamianFierce: Not often a company issues two separate statements on a single drug rejection. More | Follow @DamianFierce

> Northwest Biotherapeutics ($NWBO) watched its stock price plummet by more than 30% on Friday, as investors sold off its shares at a volume 5 times greater than average. The company issued a statement Monday saying management "is not aware of any fundamental reason for the substantial decline" in share value. Instead, Northwest "believes this activity is part of an ongoing effort to drive its stock price lower through an orchestrated campaign, including questionable short selling activity." Statement

> Novartis ($NVS) is partnering with Cambridge, MA's Luc Therapeutics to develop an NMDA modulator for depression. Neither company is disclosing financial details. More

> Bayer CEO Marijn Dekkers, stepping down at the end of next year, spoke to the Financial Times about the difference between the business climates in the U.S. and his company's native Germany. Interview

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@VarunSaxena2: #TCT15: Startup's minimally invasive mitral valve repair tech shows promise in feasibility study. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI: European investor shells out $118M for DNA testing outfit to boost animal Dx offerings. Article | Follow @EmilyWFierce

> Sientra slides amid implant manufacturing fallout in Brazil. Article

> FDA commissioner nominee stresses need to improve combination product reviews. Story

Pharma News

@FiercePharma: ICYMI: Boehringer looks for Pradaxa boost from now FDA-approved antidote. Article | Follow @FiercePharma

@EricPFierce: Pests, lack of data integrity thwart another Indian API maker, this time Unimark Remedies. More | Follow @EricPFierce

@CarlyHFierce: Shire's eye drug setback gives Allergan's Restasis a temporary reprieve. Story | Follow @CarlyHFierce

> J&J chalks up a win in first Tylenol liver-damage case to go to trial. Story

> Regeneron doubles investment, adding 200 more jobs to plant in Ireland. Article

Animal Health News

> European investor shells out $118M for DNA testing outfit to boost animal Dx offerings. Story

> Dog study validates Blaze 'tumor paint' for guiding surgery. Report

> Nexvet launches field trial of treatment for feline osteoarthritis. More

> Ceva, Harrisvaccines nab USDA contracts for bird flu vaccines. Article

> Dogs with cleft palates add to knowledge of condition in children. Story

Biotech IT News

> Venter's Human Longevity starts $50,000 health testing service. News

> LabKey lands data-management deal with 100,000 Genomes Project. More

> EU consortium creates large toxin database for drug discovery. Report

> Scripps teams up to apply genomics to stem cell quality control. Story

> 23andMe raises $115M as investors buy into data-driven drug discovery vision. Article

Pharma Marketing News

> One year after FDA nod, Eli Lilly's Trulicity launches first consumer campaign. Item

> Merck KGaA exits 'sea of sameness' with futuristic rebrand. Editor's corner

> Pacira sues for free speech; FDA pulls off-label warning letter. What gives? More

> Bayer consumer biz on digital agency hunt, in shift from 'TV-centric' to 'channel-agnostic.' Article

> Influential cancer group releases first batch of affordability info on cancer meds. Item

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.